There is precedence, in the case of STAT3, for the development of cancer, mostly large granular lymphocytic (LGL) leukemias, with somatic gain of function mutations, with much less manifestation of malignancies in patients harboring the same mutations in germline cells. This evidence concerns the gene STAT3 and cancer.